Vanguard Group Inc. Boosts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Vanguard Group Inc. increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,236,663 shares of the company's stock after purchasing an additional 307,490 shares during the quarter. Vanguard Group Inc. owned approximately 7.40% of Zentalis Pharmaceuticals worth $105,047,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Matrix Capital Management Company LP lifted its stake in Zentalis Pharmaceuticals by 51.7% in the 2nd quarter. Matrix Capital Management Company LP now owns 13,959,973 shares of the company's stock valued at $393,811,000 after acquiring an additional 4,760,000 shares in the last quarter. Eventide Asset Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 113.1% during the 2nd quarter. Eventide Asset Management LLC now owns 6,877,803 shares of the company's stock worth $194,023,000 after acquiring an additional 3,650,803 shares during the last quarter. Cormorant Asset Management LP acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at $30,890,000. State Street Corp grew its holdings in Zentalis Pharmaceuticals by 50.0% in the 2nd quarter. State Street Corp now owns 3,119,734 shares of the company's stock valued at $87,665,000 after buying an additional 1,039,294 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in Zentalis Pharmaceuticals by 15.6% in the 2nd quarter. BlackRock Inc. now owns 3,950,804 shares of the company's stock valued at $111,452,000 after buying an additional 533,337 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded down $0.24 on Friday, hitting $15.08. 377,745 shares of the company's stock were exchanged, compared to its average volume of 811,920. Zentalis Pharmaceuticals, Inc. has a 12 month low of $9.56 and a 12 month high of $31.46. The stock has a market cap of $1.07 billion, a P/E ratio of -3.35 and a beta of 1.73. The company has a 50 day moving average of $13.67 and a 200 day moving average of $14.68.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.09. Sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Wedbush increased their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a "neutral" rating in a report on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $38.57.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is owned by corporate insiders.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.